Agalaia Therapeutics
Agalaia Therapeutics is a biotech specialized in the development of new therapies to combat cancer disease.
Agalaia Therapeutics has raised €4.0M across 1 funding round from 3 investors, most recently a Seed round in Sep 2021. Based in Paris, France; active in Healthtech. Data as of 28 Oct 2026.
Paris, France
Total raised
€4.0M
€4,000,000
Funding rounds
1
Investors
3
distinct backers
Active since
2021-09
latest 2021-09
Funding by year
EUR raised per yearAgalaia Therapeutics — funding by year — interactive chart.
Data table
| Agalaia Therapeutics — funding by year | |
|---|---|
| 2021 | €4.0M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Seed
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-09-27 | Seed | €4.0M | Advent France Biotechnology,Crédit Mutuel Innovation,Pierre Fabre | View deal → |
Related news
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData